Vertex Pharma (VRTX) Tops Q3 EPS by 30c; raises guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $546.12 -2.12%
Revenue Growth %: +10.7%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +10.7%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $4.38, $0.30 better than the analyst estimate of $4.08. Revenue for the quarter came in at $2.77 billion versus the consensus estimate of $2.69 billion.
GUIDANCE:
Vertex Pharma sees FY2024 revenue of $10.8-10.9 billion, versus the consensus of $10.759 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral
- JPMorgan Starts Bechtle AG (BC8:GR) (BECTY) at Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
